2023/06/30 更新

写真a

エンドウ ヤスミ
遠藤 康実
Endoh Yasumi
所属
付属病院 臨床検査部 病院講師
職名
病院講師
外部リンク

研究キーワード

  • S100A8

  • resolution

研究分野

  • ライフサイエンス / 人体病理学  / gene regulation

学歴

  • University of New South Wales   School of Medical Sciences   PhD course

    2004年3月 - 2008年6月

      詳細を見る

  • 日本医科大学   Cardiology   PhD course

    2002年11月

      詳細を見る

  • 日本医科大学

    1982年4月 - 1988年3月

      詳細を見る

経歴

  • 日本医科大学

      詳細を見る

  • 日本医科大学   Department of cardiology   research associate

      詳細を見る

論文

  • TLR9 Ligands Induce S100A8 in Macrophages via a STAT3-Dependent Pathway which Requires IL-10 and PGE(2) 査読

    Kenneth Hsu, Yuen Ming Chung, Yasumi Endoh, Carolyn L. Geczy

    PLOS ONE   9 ( 8 )   e103629   2014年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    S100A8 and S100A9 are highly-expressed calcium-binding proteins in neutrophils and monocytes, and in subsets of macrophages in inflammatory lesions. Unmethylated CpG motifs found in bacterial and viral DNA are potent activators of innate immunity via Toll-like receptor 9 (TLR9). S100A8, but not S100A9, mRNA and protein was directly induced by CpG-DNA in murine and human macrophages. Induction in murine macrophages peaked at 16 h. CpG-DNA-induced S100A8 required de novo protein synthesis; IL-10 and Prostaglandin E-2 (PGE(2)) synergistically enhanced expression and promoted earlier gene induction. Inhibitors of endogenous IL-10, PGE2, and the E prostanoid (EP) 4 receptor strongly suppressed S100A8 expression, particularly when combined. Thus, S100A8 induction by E. coli DNA required both IL-10 and PGE(2)/EP4 signaling. The MAPKs, PI3K and JAK pathways were essential, whereas ERK1/2 appeared to play a direct role. S100A8 induction by CpG-DNA was controlled at the transcriptional level. The promoter region responsible for activation, either directly, or indirectly via IL-10 and PGE(2), was located within a -178 to -34-bp region and required STAT3 binding. Because of the robust links connecting IL-10 and PGE(2) with an anti-inflammatory macrophage phenotype, the induction profile of S100A8 strongly indicates a role for this protein in resolution of

    DOI: 10.1371/journal.pone.0103629

    Web of Science

    researchmap

  • Relationship between left ventricular dyssynchrony and systolic dysfunction is independent of impaired left ventricular myocardial perfusion in heart failure: Assessment with 99mTc-sestamibi gated myocardial scintigraphy 査読

    Hideki Miyachi, Akira Yamamoto, Toshiaki Otsuka, Masatomo Yoshikawa, Eitaro Kodani, Yasumi Endoh, Akihiro Nakagomi, Yoshiki Kusama, Hirotsugu Atarashi, Kyoichi Mizuno

    International Journal of Cardiology   167 ( 3 )   930 - 935   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Backgrounds: Left ventricular (LV) dyssynchrony reduces LV systolic function in patients with heart failure (HF). However, it remains unknown whether this relationship is independent of impaired LV myocardial perfusion. Methods and results: A total of 105 patients with chronic HF (age 71 ± 13 years
    71 men) were enrolled in the present study. 99mTc-sestamibi (MIBI) gated myocardial scintigraphy was performed at rest to assess LV myocardial perfusion as evaluated by the total defect score of perfusion Single Photon Emission Computed Tomography images (TDS-MIBI), LV systolic function as evaluated by LV ejection fraction (LVEF), and LV systolic dyssynchrony as evaluated by the maximal difference of time to end systole (MD-TES), which is the time lag between the earliest and the latest end systole among 17 LV segments analyzed with a novel program, "cardioGRAF". The mean ± SD (minimum and maximum range) of the MD-TES was 147.8 ± 117.5 (14.0-458.3) ms. The MD-TES was significantly higher in patients with LVEF &lt
    45% (199.4 ± 117.6 ms) than in those with LVEF ≥ 45% (60.5 ± 41.2 ms, p &lt
    0.001). In a multiple logistic regression analysis, the MD-TES showed an increased odds ratio for LVEF &lt
    45% (2.46 [95% CI
    1.51-4.01] per increment in decile of MD-TES rank, p &lt
    0.001), after adjusting for the TDS-MIBI, history of myocardial infarction, and other potential confounders. Conclusions: LV dyssynchrony is a significant determinant of LV systolic dysfunction in patients with HF, and this relationship is independent of impaired LV myocardial perfusion and history of myocardial infarction.

    DOI: 10.1016/j.ijcard.2012.03.091

    Scopus

    PubMed

    researchmap

  • Effects of Statin Therapy on the Production of Monocyte Pro-Inflammatory Cytokines, Cardiac Function, and Long-Term Prognosis in Chronic Heart Failure Patients With Dyslipidemia 査読

    Akihiro Nakagomi, Yoshihiko Seino, Keiichi Kohashi, Munenori Kosugi, Yasumi Endoh, Yoshiki Kusama, Hirotsugu Atarashi, Kyoichi Mizuno

    CIRCULATION JOURNAL   76 ( 9 )   2130 - 2138   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPANESE CIRCULATION SOC  

    Background: The effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function and the long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear.
    Methods and Results: A total of 146 CHF patients with a mean left ventricular ejection fraction (LVEF) of 26.9 +/- 6.6% were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=63) and a no statin group (n=83). Only patients with dyslipidemia were treated with statins. Peripheral blood mononuclear cells (PBMCs) were isolated, and the production of monocyte tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 were measured at baseline and after 6 months of treatment, and the data expressed as mean +/- SD (pg.ml(-1).10(-6) PBMCs). The LVEF in the statin group improved, and the monocyte TNF-alpha and IL-6 production decreased (respectively, P<0.001), but the LVEF and cytokine production remained unchanged in the no statin group. Multivariate Cox hazard analysis showed that statin therapy (hazard ratio, 0.14; 95% confidence interval: 0.02-0.97, P=0.046) was an independent predictor of cardiac events.
    Conclusions: Statin therapy attenuates the production of monocyte pro-inflammatory cytokines, and ameliorates the cardiac function and may improve long-term prognosis in CHF patients with dyslipidemia. (Circ J 2012; 76: 2130-2138)

    DOI: 10.1253/circj.CJ-11-1123

    Web of Science

    researchmap

  • LILRA2 Selectively Modulates LPS-Mediated Cytokine Production and Inhibits Phagocytosis by Monocytes 査読

    Hao K. Lu, Ainslie Mitchell, Yasumi Endoh, Taline Hampartzoumian, Owen Huynh, Luis Borges, Carolyn Geczy, Katherine Bryant, Nicodemus Tedla

    PLOS ONE   7 ( 3 )   e33478   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    The activating immunoglobulin-like receptor, subfamily A, member 2 (LILRA2) is primarily expressed on the surface of cells of the innate immunity including monocytes, macrophages, neutrophils, basophils and eosinophils but not on lymphocytes and NK cells. LILRA2 cross-linking on monocytes induces pro-inflammatory cytokines while inhibiting dendritic cell differentiation and antigen presentation. A similar activating receptor, LILRA4, has been shown to modulate functions of TLR7/9 in dendritic cells. These suggest a selective immune regulatory role for LILRAs during innate immune responses. However, whether LILRA2 has functions distinct from other receptors of the innate immunity including Toll-like receptor (TLR) 4 and Fc gamma RI remains unknown. Moreover, the effects of LILRA2 on TLR4 and Fc gamma RI-mediated monocyte functions are not elucidated. Here, we show activation of monocytes via LILRA2 cross-linking selectively increased GM-CSF production but failed to induce IL-12 and MCP-1 production that were strongly up-regulated by LPS, suggesting functions distinct from TLR4. Interestingly, LILRA2 cross-linking on monocytes induced similar amounts of IL-6, IL-8, G-CSF and MIP-1 alpha but lower levels of TNF alpha, IL-1 beta, IL-10 and IFN gamma compared to those stimulated with LPS. Furthermore, cross-linking of LILRA2 on monocytes significantly decreased phagocytosis of IgG-coated micro-beads and serum opsonized Escherichia coli but had limited effect on phagocytosis of non-opsonized bacteria. Simultaneous co-stimulation of monocytes through LILRA2 and LPS or sequential activation of monocytes through LILRA2 followed by LPS led lower levels of TNF alpha, IL-1 beta and IL-12 production compared to LPS alone, but had additive effect on levels of IL-10 and IFN gamma but not on IL-6. Interestingly, LILRA2 cross-linking on monocytes caused significant inhibition of TLR4 mRNA and protein, suggesting LILRA2-mediated suppression of LPS responses might be partly via regulation of this receptor. Taken together, we provide evidence that LILRA2-mediated activation of monocytes is significantly different to LPS and that LILRA2 selectively modulates LPS-mediated monocyte activation and Fc gamma RI-dependent phagocytosis.

    DOI: 10.1371/journal.pone.0033478

    Web of Science

    researchmap

  • S100A8 Modulates Mast Cell Function and Suppresses Eosinophil Migration in Acute Asthma 査読

    Jing Zhao, Ikuko Endoh, Kenneth Hsu, Nicodemus Tedla, Yasumi Endoh, Carolyn L. Geczy

    ANTIOXIDANTS & REDOX SIGNALING   14 ( 9 )   1589 - 1600   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MARY ANN LIEBERT, INC  

    S100A8 is implicated in the pathogenesis of inflammatory diseases. S100A8 is upregulated in macrophages by Toll-like receptors (TLR)-3, 4, and 9 agonists in an IL-10-dependent manner, and by corticosteroids in vitro and in vivo, and scavenges oxidants generated by activated phagocytes. Because if its elevated expression in various lung disorders, we asked whether S100A8 was protective in allergic inflammation. S100A8, but not Cys(41)-Ala S100A8, in which the single reactive Cys residue was replaced by Ala, reduced mast cell (MC) degranulation and production of particular cytokines (IL-6, IL-4, and granulocyte macrophage colony-stimulating factor) in response to IgE-crosslinking in vitro, likely by inhibiting intracellular reactive oxygen species production, thereby reducing downstream linker for activation of T cells and extracellular signal regulated kinase/mitogen-activated protein kinase phosphorylation. In lungs of mice with acute asthma, S100A8, but not Cys(41)-Ala S100A8, reduced MC degranulation, production of eosinophil chemoattractants (IL-5, eotaxin, and monocyte chemoattractant protein-1), and eosinophil infiltration. Suppression of IL-6 and IL-13 could have contributed to reduced mucus production seen in lungs of S100A8-treated mice. IgE production was unaffected. In asthma, there is an imbalance of anti-oxidant systems that are generally protective. Our results strongly support a protective role for S100A8 in allergic inflammation by modulating MC activation and eosinophil recruitment, and by scavenging oxidants generated by activated leukocytes, in processes reliant on its thiol-scavenging capacity. Antioxid. Redox Signal. 14, 1589-1600.

    DOI: 10.1089/ars.2010.3583

    Web of Science

    researchmap

  • Upregulation of Monocyte Tissue Factor Activity is Significantly Associated with Carotid Intima-Media Thickness in Patients with Metabolic Syndrome 査読

    Akihiro Nakagomi, Mihoko Sasaki, Youhei Ishikawa, Toshiyuki Shibui, Munenori Kosugi, Yasumi Endoh, Masako Morikawa, Yoshiki Kusama, Hirotsugu Atarashi, Kyoichi Mizuno

    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS   18 ( 6 )   475 - 486   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN ATHEROSCLEROSIS SOC  

    Aims: Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors and an increased risk of cardiovascular events. The carotid intima-media thickness (CIMT) is correlated with coronary and carotid atherosclerosis, and is a significant predictor of cardiovascular events. Tissue factor (TF) is an initiator of the extrinsic coagulation cascade and is expressed on peripheral blood monocytes and macrophages in atherosclerotic plaques. TF plays important roles in both thrombosis and atherosclerosis. No study has investigated the relationship between monocyte TF activity and CIMT in MS patients.
    Methods: Peripheral blood mononuclear cells (PBMCs) were collected from 39 normal subjects and 110 patients with MS. The procoagulant activity (PCA) in monocytes was measured using a one-stage clotting assay and is expressed as the mean +/- SD (mU TF/10(6) PBMCs).
    Results: The PCA in monocytes in MS patients was significantly higher than in normal subjects (86.2 +/- 69.5 vs. 52.4 +/- 9.9 mU TF/10(6) PBMCs, p < 0.001). In multivariate analysis, patient age (beta coefficient = 0.373, p < 0.001), high-density lipoprotein cholesterol (beta coefficient = -0.307, p = 0.001) and PCA (beta coefficient = 0.422, p = 0.002) were each significantly and independently associated with CIMT.
    Conclusions: These data indicate that the upregulation of monocyte TF activity is significantly associated with CIMT in MS patients.

    DOI: 10.5551/jat.6874

    Web of Science

    researchmap

  • Upregulation of Monocyte Proinflammatory Cytokine Production by C-Reactive Protein is Significantly Related to Ongoing Myocardial Damage and Future Cardiac Events in Patients With Chronic Heart Failure 査読

    Akihiro Nakagomi, Yoshihiko Seino, Yasumi Endoh, Yoshiki Kusama, Hirotsugu Atarashi, Kyoichi Mizuno

    JOURNAL OF CARDIAC FAILURE   16 ( 7 )   562 - 571   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS  

    Background: An elevation of the cardiac troponin T (TnT) level identifies patients with ongoing myocardial damage (OMD) and at increased risk for future cardiac events in chronic heart failure (CHF). C-reactive protein (CRP) upregulates monocyte proinflammatory cytokine production and this upregulalion appears to play an important role on OMD.
    Methods and Results: Peripheral blood mononuclear cells (PBMCs) were stimulated by 25 mu g/mL CRP in 72 patients with CHF. Tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production by monocytes was measured by a specific enzyme-linked immunosorbent assay and expressed as the mean +/- SD (pg.mL.10(6) PBMCs). The patients were divided into 2 groups according to the TnT levels: 27 patients with OMD (TnT >= 0.01 ng/mL) and 45 patients without OMD. CRP-induced cytokine production was upregulated significantly more in patients with OMD than in those without OMD (TNF-alpha.: 200.6 +/- 100.4 vs. 102.1 +/- 73.6 pg/mL, P < .001, IL-6: 4611.7 +/- 2600.0 vs. 1451.6 +/- 1193.5 pg/mL, P < .001). Multivariate Cox regression analyses revealed that CRP-stimulated monocyte production of TNF-alpha 120 pg/mL and TnT >= 0.03 ng/mL were independent predictors of cardiac events.
    Conclusions: The upregulation of monocyte proinflammatory cytokine production by CRP could be significantly related to OMD and future cardiac events in CHF. (J Cardiac Fail 2010;16:562-571)

    DOI: 10.1016/j.cardfail.2010.02.003

    Web of Science

    researchmap

  • IL-10-Dependent S100A8 Gene Induction in Monocytes/Macrophages by Double-Stranded RNA 査読

    Yasumi Endoh, Yuen Ming Chung, Ian A. Clark, Carolyn L. Geczy, Kenneth Hsu

    JOURNAL OF IMMUNOLOGY   182 ( 4 )   2258 - 2268   2009年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC IMMUNOLOGISTS  

    The S100 calcium-binding proteins S100A8 and S100A9 are elevated systemically in patients with viral infections. The S100A8-S100A9 complex facilitated viral replication in human CD4(+) T lymphocytes latently infected with HIV-1- and S100A8-induced HIV-1 transcriptional activity. Mechanisms inducing the S100 genes and the potential source of these proteins following viral activation are unknown. In this study, we show that S100A8 was induced in murine macrophages, and S100A8 and S100A9 in human monocytes and macrophages, by polyinosinic: polycytidylic acid, a dsRNA mimetic. Induction was at the transcriptional level and was IL-10 dependent. Similar to LPS-induced S100A8, induction by dsRNA was dependent on p38 and ERK MAPK. Protein kinase R (PKR) mediates antiviral defense and participates in MyD88-dependent/independent signaling triggered by TLR4 or TLR3. Like IL-10, S100 induction by polyinosinic:polycytidylic acid and by LPS was inhibited by the specific PKR inhibitor 2-aminopurine, indicating a novel IL-10, PKR-dependent pathway. Other mediators such as IFN-beta, which synergized with dsRNA, may also be involved. C/EBP beta bound the defined promoter region in response to dsRNA. S100A8 was expressed in lungs of mice infected with influenza virus and was maximal at day 8 with strong immunoreactivity in epithelial cells lining the airways and in mononuclear cells and declined early in the recovery phase, implying down-regulation by mediator(s) up-regulated during resolution of the infection. IL-10 is implicated in viral persistence. Since S100A8/S100A9 levels are likely to be maintained in conditions where IL-10 is raised, these proteins may contribute to viral persistence in patients infected by some RNA viruses. The Journal of Immunology, 2009, 182: 2258-2268.

    DOI: 10.4049/jimmunol.0802683

    Web of Science

    researchmap

  • LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and is regulated by TNF-alpha, IL-10 and IFN-gamma 査読

    Ainslie Mitchell, Carles Rentero, Yasumi Endoh, Kenneth Hsu, Katharina Gaus, Carolyn Geczy, H. Patrick McNeil, Luis Borges, Nicodemus Tedla

    EUROPEAN JOURNAL OF IMMUNOLOGY   38 ( 12 )   3459 - 3473   2008年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-V C H VERLAG GMBH  

    Leukocyte immunoglobulin-like receptor A5 (LILRA5) belongs to a family of receptors known to regulate leukocyte activation, There are two membrane-bound and two soluble forms of LILRA5. The transmembrane LILRA5 contain a short cytoplasmic domain and a charged arginine residue within the transmembrane region. Cross-linking of LILRA5 on monocytes induced production of pro-inflammatory cytokines, suggesting that LILRA5 plays a role in inflammation. However, expression of LILRA5 in diseases with extensive inflammatory component is unknown. Rheumatoid arthritis (RA) is a chronic inflammatory synovitis characterized by unregulated activation of leukocytes leading to joint destruction. Here we demonstrate extensive LILRA5 expression on synovial tissue macrophages and in synovial fluid of patients with active RA but not in patients with osteoarthritis. We also show that LILRA5 associated with the common gamma chain of the FcR and LILRA5 cross-linking induced phosphorylation of Src tyrosine kinases and Spleen tyrosine kinase (Syk). Furthermore, LILRA5 induced selective production of pro-inflammatory cytokines as well as IL-10. LILRA5 mRNA and protein expression was tightly regulated by TNF-alpha, IL-10 and IFN-gamma. Increased expression of LILRA5 in rheumatoid tissue, together with its ability to induce key cytokines involved in RA, suggests that this novel receptor may contribute to disease pathogenesis.

    DOI: 10.1002/eji.200838415

    Web of Science

    researchmap

  • New mechanisms modulating S100A8 gene expression 査読

    Endoh Y

    University of New South Wales   2008年

     詳細を見る

  • Regulation of S100A8 by glucocorticoids 査読

    Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T, Geczy CL

    J Immunol   174   2318 - 2326   2008年

     詳細を見る

  • FGF-2, IL-1β and TGF-β regulate fibroblast expression of S100A8 査読

    Rahimi F, Hsu K, Endoh Y, Geczy CL

    FEBS J   272 ( 11 )   2811 - 2827   2005年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/j.1742-4658.2005.04703.x

    Web of Science

    researchmap

  • Electrocardiographic and electrophysiological chraracteristics of into atrial flutter by oral administration of Class I antiarrhythmic agents 査読

    Ohmura K, Kobayashi Y, Miyauchi Y, EndohY, Atarashi H, Katoh T, Takano T

    PACE   26   1 - 11   2003年

     詳細を見る

  • Clinical significance of wide QRS complexes at the termination of paroxysmal supraventricular tachycardias 査読

    Yasumi Endoh, Hirotsugu Atarashi, Hirokazu Hayakawa, Kouichi Nagasawa, Hiroshi Kishida, Teruo Takano

    Journal of Nippon Medical School   69 ( 6 )   525 - 533   2002年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: A wide QRS complex is not a rare electrocardiographic phenomenon at the termination of paroxysmal supraventricular tachycardia (PSVT), but no plausible underlying mechanism has yet been proposed. The purpose of the present study was to elucidate the frequency and the underlying mechanism of the wide QRS complexes at the termination of PSVT. Methods: We retrospectively reviewed 305 electrocardiograms (ECGs) from 100 patients, on which PSVT termination was recorded. The frequency of the wide QRS complexes was analyzed in 181 ECGs to avoid duplication, because there were 124 ECGs obtained from the same patients with same methods. The 181 ECGs were divided by morphology into three groups: Type A, termination with wide QRS complex without pause
    Type B, wide QRS complex following initial pause after termination
    Type C, wide QRS complex following the first narrow QRS after termination. Results: The wide QRS complex was recorded in 81/181 (44.8%) ECGs (Type A
    3/81 (3.7%), Type B
    44/81 (54.3%), Type C
    62/81 (55.6%)) and its frequency was not dependent on the mechanism of PSVT. It was more frequently observed after a long pause, and was frequently induced by procedures that increase vagal tone, such as intravenous adenosine 5′-triphosphate administration (16/22:72.7%) and vagal stimulation maneuvers (16/32:50%). There were a total of 41 wide QRS complexes (44.6%) which had a preceding sinus P wave, out of a total of 92 wide QRS complexes in all three types. These 41 wide QRS complexes included 30/44 (68.2%) Type B wide QRS, and 11 (24.4%) Type C wide QRS complexes. Conclusion. The aberrant conduction or escaped ventricular contraction was suggested to be the underlying mechanism of the majority of wide QRS complexes and ventricular premature contraction is less frequent.

    DOI: 10.1272/jnms.69.525

    Scopus

    PubMed

    researchmap

  • Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias 査読

    H Atarashi, A Kuruma, M Yashima, H Saitoh, T Ino, Y Endoh, H Hayakawa

    CLINICAL PHARMACOLOGY & THERAPEUTICS   68 ( 2 )   143 - 150   2000年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MOSBY, INC  

    Objectives: To elucidate pharmacokinetics and pharmacodynamics of landiolol hydrochloride, newer developed ultra-short-acting beta-blocker, in patients with various cardiac tachyarrhythmias.
    Background: The short duration of action and titratability of landiolol hydrochloride make it ideal for use in patients with a clinical need for beta-blockers.
    Methods: In a total of 31 examinations we infused the drug in 19 patients (mean age, 55 +/- 14 years). After the persistence of the tachyarrhythmias was confirmed, continuous infusion was started at rates of 0.005, 0.01, 0.02, 0.04, and 0.08 mg/kg/min for 5 minutes (for paroxysmal atrial fibrillation, paroxysmal supraventricular tachycardia, and ventricular tachycardia) or 15 minutes (for ventricular premature complex). We analyzed the pharmacokinetics of 16 examinations. A one-compartment model provided a close fit for each blood concentration-time curve.
    Results: The maximum blood concentrations obtained clearly showed the dose dependency and revealed very short half-lives (range, 2.3 to 4.0 minutes). Area under the blood concentration-time curves also increased, showing dose dependency. In paroxysmal atrial fibrillation, landiolol hydrochloride reduced the heart rate from 111 +/- 20 to 90 +/- 10/min. Sinus rhythm was restored, without any adverse effects, in three of five patients with paroxysmal supraventricular tachycardia and one patient with ventricular tachycardia, There was no significant change in peripheral blood pressure,
    Conclusions: Landiolol hydrochloride has a shorter elimination half-life than any other beta-blocker, and it can be administered safely to patients with various tachyarrhythmias.

    DOI: 10.1067/mcp.2000.108733

    Web of Science

    researchmap

  • Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias 査読

    H Atarashi, Y Endoh, H Saitoh, H Kishida, H Hayakawa

    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY   31 ( 4 )   534 - 539   1998年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Whether phosphodiesterase inhibitors increase the heart rate in patients with bradyarrhythmias is not known. We attempted to determine whether the oral phosphodiesterase inhibitor cilostazol exhibits beneficial chronotropic effects in patients with symptomatic bradyarrhythmias. Twenty patients comprising eight with bradycardic atrial fibrillation, eight with sick sinus syndrome, and four with Wenckebach-type atrioventricular block, whose 24-h total heart-beat count was less than or equal to 70,000 brats and whose maximal RR interval was greater than or equal to 2.5 s, were enrolled. Holter recordings (24-h) were made before and 2 weeks after oral daily administration of 200 mg of cilostazol. Cilostazol increased the 24-h total heart-beat count from 77,429 +/- 11,168 to 107,981 +/- 13,536 (95% confidence interval, 24,605-36,397; p < 0.0001), the minimal heart rate from 33 +/- 9 47 +/- 13 beats/min (95% confidence interval, 9-19 beats/min; p < 0.0001), and the maximal RR interval from 3,149 +/- 1,018 to 2,087 +/- 601 ms (95% confidence interval, -1,517 to -608 ms; p = 0.0001). Only two patients had headaches as adverse effects. In conclusion, cilostazol had a beneficial positive chronotropic effect in patients with bradyarrhythmias, especially with bradycardic atrial fibrillation and sick sinus syndrome.

    DOI: 10.1097/00005344-199804000-00010

    Web of Science

    researchmap

  • Curative percutaneous catheter ablation for various supraventricular and ventricular tachyarrhythmias 査読

    Kobayashi Y, Ino T, Miyauchi Y, Kawaguchi N, Ogura H, Ohmura K, Ohara T, Tadera T, Endoh Y, Yashima M, Kuruma A, Onodera T, Saitoh H, Atarashi H, Katoh T, Kishida H, Hayakawa H

    J Nippon Med Sch   64   546 - 565   1997年

▼全件表示